Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAR-Immune
2024-513982-38-00Phase 3Completed
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in angiosarcoma, alveolar soft part sarcoma (ASPS), clear cell sarcoma (CCS) and 16 more comparing nivolumab + ipilimumab with pazopanib (2 arms). Primary endpoint: Progression-Free Survival. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
angiosarcomaalveolar soft part sarcoma (ASPS)clear cell sarcoma (CCS)desmoplastic small round cell tumor (DSRCT)sclerosing epithelioid fibrosarcoma (SEF)
Beyond the preview
Go deeper on 2024-513982-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513982-38-00.